Company: ELV
Filing Date: 2025-09-08
Form Type: 424B3
Source: 0001193125-25-197796
Chunk: 65

Company: Elevance Health, Inc.
Filing Date: 2025-09-08
Form: 424B3
Chunk 65
---
     | Elevance Health’s 5.100% senior unsecured notes due 2044; |

| • |     | Elevance Health’s 4.650% senior unsecured notes due 2044; |

| • |     | Elevance Health’s 4.375% senior unsecured notes due 2047; |

| • |     | Elevance Health’s 4.550% senior unsecured notes due 2048; |

| • |     | Elevance Health’s 3.700% senior unsecured notes due 2049; |

| • |     | Elevance Health’s 3.125% senior unsecured notes due 2050; |

| • |     | Elevance Health’s 3.600% senior unsecured notes due 2051; |

| • |     | Elevance Health’s 4.550% senior unsecured notes due 2052; |

| • |     | Elevance Health’s 6.100% senior unsecured notes due 2052; |

| • |     | Elevance Health’s 5.125% senior unsecured notes due 2053; and |

| • |     | Elevance Health’s 4.850% senior unsecured notes due 2054 |

are outstanding. The Bank of New York Mellon Trust Company, N.A. also is the fiscal agent under the fiscal agency agreement pursuant to which Anthem Insurance Companies, Inc.’s 9.000% surplus notes due 2027 are outstanding. The Bank of New York Mellon Corporation, an affiliate of the trustee, also performs services for us in the ordinary course of business. 18

DESCRIPTION OF THE PREFERRED STOCK This section describes the general terms and provisions of the preferred stock we may offer by this prospectus. The applicable prospectus supplement will describe the specific terms of the series of the preferred stock then offered, and the terms and provisions described in this section will apply only to the extent not superseded by the terms of the applicable prospectus supplement. Because this is only a summary, it does not contain all of the terms applicable to the preferred stock that we may offer. We urge you to read carefully our amended and restated articles of incorporation, as amended (our “articles of incorporation”), and the articles of amendment we have filed or will file in relation to an issue of any particular series of preferred stock before you buy any preferred stock. We are authorized to issue up to 100,000,000 shares of preferred stock, without par